A new drug hopes to improve the effectiveness of cancer treatment in patients with certain types of stomach and oesophageal tumours.
According to Cancer Research UK, 18 per cent of patients with stomach cancer survive for five or more years, while only 13 per cent of those with tumours in the oesophagus live that long.
Part of the reason for this low survival rate is the higher than average presence of a protein called fibroblast growth factor receptor-2 (FGFR2), which makes tumours less responsive to existing therapies.
However, scientists at the Glasgow Cancer Research UK and Scottish Health Department's Experimental Cancer Medicine Centre and the Cancer Research UK Glasgow Clinical Trials Unit hope to inhibit FGFR2 with a new drug from AstraZeneca.
"We hope this trial will be an important step forward in finding a more effective treatment approach - ultimately improving survival from these diseases," said Professor Jeff Evans, lead investigator of the study.